- $55.54m
- $61.61m
- $0.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 828.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -61745.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2 | 14 | n/a | 0 | 0.06 | 5.64 | 16.99 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eyenovia, Inc. is an ophthalmic technology company. The Company is developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its potential for superior compliance versus standard eye drops. The Company’s commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi for mydriasis. Mydcombi is an FDA-approved fixed combination of the two pupil dilation drugs, tropicamide and phenylephrine, delivered with its Optejet technology. The product is indicted to induce mydriasis (pupil dilation) for routine diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroLine is its investigational proprietary microdosed version of pilocarpine, an ophthalmic medication that can dose-dependently induce miosis, or contraction of the pupil.
Directors
- Tsontcho Ianchulev CEO (47)
- John Gandolfo CFO (61)
- Michael Rowe COO (59)
- Jennifer Clasby VPR (67)
- Luke Clauson VRD (43)
- Curt Labelle DRC (50)
- Stephen Benjamin IND
- Julia Haller IND (66)
- Rachel Jacobson IND
- Kenneth Lee IND (73)
- Charles Mather IND (60)
- Anthony Sun IND (49)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- July 23rd, 2014
- Public Since
- January 25th, 2018
- No. of Shareholders
- 32
- No. of Employees
- 13
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 5,104,355
- Address
- 295 Madison Ave Ste 2400, NEW YORK, 10017
- Web
- https://eyenovia.com/
- Phone
- +1 8137669539
- Contact
- Eric Ribner
- Auditors
- Marcum LLP
Upcoming Events for EYEN
Q2 2025 Eyenovia Inc Earnings Release
Q3 2025 Eyenovia Inc Earnings Release
Similar to EYEN
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
What is the Eyenovia share price?
As of Today at 20:33 UTC, shares in Eyenovia are trading at $10.88. This share price information is delayed by 15 minutes.
How has the Eyenovia share price performed this year?
Shares in Eyenovia last closed at $10.88 and the price had moved by -80.35% over the past 365 days. In terms of relative price strength the Eyenovia share price has underperformed the S&P500 Index by -82.62% over the past year.
What are the analyst and broker recommendations for Eyenovia?
The overall consensus recommendation for Eyenovia is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Eyenovia dividend yield?
Eyenovia does not currently pay a dividend.
Does Eyenovia pay a dividend?
Eyenovia does not currently pay a dividend.
When does Eyenovia next pay dividends?
Eyenovia does not currently pay a dividend.
How do I buy Eyenovia shares?
To buy shares in Eyenovia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eyenovia?
As of the previous close price of $10.88, shares in Eyenovia had a market capitalisation of $55.54m.
Where are Eyenovia shares listed?
Here are the trading details for Eyenovia:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EYEN
What kind of share is Eyenovia?
Based on an overall assessment of its quality, value and momentum Eyenovia is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eyenovia share price forecast for 2025?
The analyst consensus target price for shares in Eyenovia is $160.00. That is 1370.59% above the last closing price of $10.88.
Analysts covering Eyenovia currently have a consensus Earnings Per Share (EPS) forecast of -$36.80 for the next financial year.
Find out moreWhat is the trend in the Eyenovia share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eyenovia. Over the past six months, its share price has outperformed the S&P500 Index by +38.15%.
As of the last closing price of $10.88, shares in Eyenovia were trading -12.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eyenovia PE Ratio?
The Eyenovia PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eyenovia?
Eyenovia's management team is headed by:
- Tsontcho Ianchulev - CEO
- John Gandolfo - CFO
- Michael Rowe - COO
- Jennifer Clasby - VPR
- Luke Clauson - VRD
- Curt Labelle - DRC
- Stephen Benjamin - IND
- Julia Haller - IND
- Rachel Jacobson - IND
- Kenneth Lee - IND
- Charles Mather - IND
- Anthony Sun - IND